Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ib Trial of Two Folate Binding Protein (FBP) Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients

Trial Profile

Phase Ib Trial of Two Folate Binding Protein (FBP) Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 15 May 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GALE 301 (Primary) ; GALE 302 (Primary)
  • Indications Breast cancer; Ovarian cancer
  • Focus Therapeutic Use
  • Sponsors Galena Biopharma
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 09 Mar 2017 Status changed from active, no longer recruiting to completed, as reported in a Galena Biopharma media release.
    • 12 Dec 2016 According to a Galena Biopharma media release, data from this study were presented as a poster at the San Antonio Breast Cancer Symposium (SABCS).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top